Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA; North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly & Company. Ma CX, et al. Among authors: jett jr. J Clin Oncol. 2005 Sep 1;23(25):5929-37. doi: 10.1200/JCO.2005.13.953. J Clin Oncol. 2005. PMID: 16135464 Clinical Trial.
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.
Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, Gerstner JB, Maksymiuk A, Levitt R, Mailliard JA, Tazelaar HD, Hillman S, Jett JR. Bonner JA, et al. Among authors: jett jr. J Clin Oncol. 1999 Sep;17(9):2681-91. doi: 10.1200/JCO.1999.17.9.2681. J Clin Oncol. 1999. PMID: 10561342 Clinical Trial.
Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K Jr, Wender DB, Soori G, Perez EA, Jett JR. Bryce AH, et al. Am J Clin Oncol. 2010 Aug;33(4):353-7. doi: 10.1097/COC.0b013e3181b0c27f. Am J Clin Oncol. 2010. PMID: 19935387 Free PMC article. Clinical Trial.
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Reungwetwattana T, et al. Among authors: jett jr. J Thorac Oncol. 2012 May;7(5):919-22. doi: 10.1097/JTO.0b013e31824de0d6. J Thorac Oncol. 2012. PMID: 22722792 Free PMC article. Clinical Trial.
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Kumar SK, et al. Among authors: jett j. Invest New Drugs. 2013 Oct;31(5):1201-6. doi: 10.1007/s10637-013-0004-2. Epub 2013 Jul 26. Invest New Drugs. 2013. PMID: 23887852 Free PMC article. Clinical Trial.
363 results